Head of Investor Relations
Agios Pharmaceuticals, Inc. (AGIO)Equibles does not estimate personal net worth.
Get an email with a short summary when Agios Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get AGIO alertsMorgan Sanford is recorded as Head of Investor Relations at Agios Pharmaceuticals, Inc. (AGIO). Morgan Sanford has spoken on 4 earnings calls and 3 other investor events across 1 company, most recently for Agios Pharmaceuticals, Inc. on September 9, 2026. Agios Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Agios Pharmaceuticals, Inc. includes Brian Goff (CEO and Board Member), Jacqualyn Fouse (CEO and Board Member), David P. Schenkein (Chairman) and 7 others.
“Thank you for joining us to discuss Agios Pharmaceuticals' second quarter 2026 financial results and business highlights. You can access the slides for today's call by going to the investors section of our website, agios.com. Please note we'll be making certain forward-looking statements today.”
“Thank you for joining us to discuss Agios Pharmaceuticals' second quarter 2026 financial results and business highlights. You can access the slides for today's call by going to the investors section of our website, agios.com. Please note we'll be making certain forward-looking statements today.”
“We're pleased to host today's webcast in conjunction with the 2026 EHA Congress, where we are presenting a broad set of data across our portfolio. You can access the slides for today's presentation on the Investor section of our website.”
“We're pleased to host today's webcast in conjunction with the 2026 EHA Congress, where we are presenting a broad set of data across our portfolio. You can access the slides for today's presentation on the Investor section of our website.”
“Thank you for joining us to discuss IGUES Pharmaceuticals' first quarter, 2026 Financial Results and Business Highlights. You can access the slides for today's call by going to the Investor section of our website, IGUES.com. Please note we'll be making certain forward-looking statements today.”
Biotechnology · Healthcare
Head of Investor Relations
